These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25556490)

  • 1. Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
    Xiao Y; Liu J; Huang XE; Ca LH; Ma YM; Wei W; Zhang RX; Huang XH; Chang J; Wu YJ
    Asian Pac J Cancer Prev; 2014; 15(23):10445-9. PubMed ID: 25556490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxycodone for cancer-related pain.
    Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD003870. PubMed ID: 28829910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
    Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
    Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain.
    Pan H; Zhang Z; Zhang Y; Xu N; Lu L; Dou C; Guo Y; Wu S; Yue J; Wu D; Dai Y
    Clin Drug Investig; 2007; 27(4):259-67. PubMed ID: 17358098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders.
    Hwang CJ; Chung SS; Lee KY; Lee JH; Moon SH; Kim JH; Cho KJ; Ahn JS; Kim DS; Park YS; Park HJ
    Clin Orthop Surg; 2018 Mar; 10(1):33-40. PubMed ID: 29564045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
    Dunlop W; Uhl R; Khan I; Taylor A; Barton G
    J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
    Silvestri B; Bandieri E; Del Prete S; Ianniello GP; Micheletto G; Dambrosio M; Sabbatini G; Endrizzi L; Marra A; Aitini E; Calorio A; Garetto F; Nastasi G; Piantedosi F; Sidoti V; Spanu P
    Clin Drug Investig; 2008; 28(7):399-407. PubMed ID: 18544000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
    Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
    Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial.
    Caldwell JR; Hale ME; Boyd RE; Hague JM; Iwan T; Shi M; Lacouture PG
    J Rheumatol; 1999 Apr; 26(4):862-9. PubMed ID: 10229408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin syndrome induced by fluvoxamine and oxycodone.
    Karunatilake H; Buckley NA
    Ann Pharmacother; 2006 Jan; 40(1):155-7. PubMed ID: 16368927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.
    Inoue S; Saito Y; Tsuneto S; Aruga E; Takahashi H; Uemori M
    Jpn J Clin Oncol; 2018 Jun; 48(6):542-547. PubMed ID: 29659913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.
    Kaplan R; Parris WC; Citron ML; Zhukovsky D; Reder RF; Buckley BJ; Kaiko RF
    J Clin Oncol; 1998 Oct; 16(10):3230-7. PubMed ID: 9779696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe cancer pain.
    Yu SY;
    Oncology; 2008; 74 Suppl 1():46-51. PubMed ID: 18758197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study.
    Wang W; Song Z; Zhang Y
    Med Sci Monit; 2018 Sep; 24():6750-6755. PubMed ID: 30229751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
    Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.